SJ

Sakshi Jindal

Director Director DIN 06827938
DIN 06827938 First appointment Feb 2014 Primary industry Education & Learing
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2014
Shareholding value β€’β€’β€’β€’ Premium profile

About Sakshi Jindal

Data last updated:

Sakshi Jindal was a Director at Jiyes Learning Institute (2014–2019) and Director at Biotech Study And Research Centre Private Limited (from 2014). The companies operate in Education & Learing.

DIN 06827938
Primary Designation Director
Industry Education & Learing
First Appointment 25 Feb 2014
Oldest Company Age 15 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jiyes Learning Institute U80903HR2014NPL052788
Director21 Jul 20142014₹34.1 Lakh (FY 2024)Active
Director25 Feb 20142011Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Biotech Study And Research Centre Private Limited
Jiyes Learning Institute
Premium access

Shareholding and investment profile for Sakshi Jindal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sakshi Jindal

Sakshi Jindal was first appointed on 25 Feb 2014 as Director at Biotech Study And Research Centre Private Limited.

Sakshi Jindal held 2 earlier board appointments: Jiyes Learning Institute (Director, 21 Jul 2014 to 25 Mar 2019); Biotech Study And Research Centre Private Limited (Director, from 25 Feb 2014).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available